IQVIA HOLDINGS INC.
NYSE: IQV·Research Triangle Park, North Carolina·CIK 0001478242
- Price
- $264.73
- Base IV
- $68.42
Valuation snapshot
At $264.73, the price is above even our bull case of $141.68.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $68.42
- 26% of the price · range $4.91–$141.68
- Price vs base case
- 287% above
- $264.73 against $68.42
- Base case · our researched forecast, 2026-10-28See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $4.91 to bull $141.68. Values per share.
Price against each value
- Bear case
- $4.91
- Price 5,295% above
- No growth
- …
- —
- Base case
- $68.42
- Price 287% above
What does Iqvia do?
IQVIA provides life sciences and healthcare companies with clinical research services, commercial analytics, and data infrastructure to accelerate the development and commercialization of medical treatments.
It brought in $17.3B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- Research Triangle Park, North Carolina
- Trades on
- NYSE as IQV
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 8¢ was left as profit after every cost, interest and tax. The biggest cost is everything else it takes to operate, 75¢ of every dollar.
- Sales, marketing and admin12¢
- Everything else it takes to operate75¢
- Interest and other costs4¢
- Tax1¢
- Left as profit8¢
- Other items after tax came back in+1¢
Who pays Iqvia, and for what?
IQVIA sells clinical research services, healthcare data and analytics, software, and commercial support to life sciences and healthcare organizations. It earns revenue by providing these services and solutions; it reports three 2025 business segments, which it reorganized into two segments effective January 1, 2026.
Its customers are mainly pharmaceutical, biotechnology, medical device, and consumer health companies, as well as payers, governments, healthcare providers, distributors, and pharmacies.
Research & Development Solutions
55%Clinical research and trial services, including trial management, laboratory work, and patient and site support.
IQVIA clinical research laboratory servicesImage: Iqvia Technology & Analytics Solutions
41%Healthcare data, analytics, software, consulting, and real-world evidence services.
Contract Sales & Medical Solutions
5%Contract sales teams, patient engagement, and medical services for life sciences companies.
IQVIA contract sales servicesImage: Iqvia
Where its work physically happens, beyond headquarters:
- Valencia Central Laboratory and Biorepository — Valencia, United States. The 134,000-square-foot facility combines clinical trial testing and biorepository services that support drug development customers.
- Livingston Central Laboratory — Livingston, United Kingdom. The Livingston facility provides central laboratory testing for clinical trials within IQVIA’s global laboratory network.
- Beijing Laboratory — Beijing, China. The Beijing facility combines central laboratory, genomics and bioanalytical services for clinical development work.
- Singapore Central Laboratory — Singapore, Singapore. The Singapore laboratory provides regional clinical trial testing as one of IQVIA Laboratories’ four main central laboratories.
- Marietta Immunoassay Laboratory — Marietta, United States. This 20,000-square-foot principal immunoassay facility supports high-throughput bioanalysis alongside flow cytometry, cell culture and translational sciences.
How is the business doing?
Sales grew from $11.4B in 2020 to $16.3B in 2025, about 8% a year.
Running the business leaves about 13¢ of each sales dollar as operating profit, up from 6¢ in 2020.
After paying for its upkeep and new investment, it had $2.1B of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
IQVIA says its mission is to accelerate innovation for a healthier world.
“Accelerate innovation for a healthier world”
What management says it is working on now:
Connect data, analytics, technology, and expertise
Management describes IQVIA Connected Intelligence as a way to help clients improve clinical trials, generate healthcare evidence, and run clinical and commercial operations more efficiently.
IQVIA Holdings Inc. 2025 Form 10-K, Item 1: Growth StrategyExpand client relationships and reach
The company aims to build on its global client base and offer more research, development, and commercial services to existing clients.
IQVIA Holdings Inc. 2025 Form 10-K, Item 1: Growth StrategyServe more of healthcare
Management sees opportunities to apply its technology and expertise for payers, providers, governments, and other healthcare groups.
IQVIA Holdings Inc. 2025 Form 10-K, Item 1: Growth StrategyInvest in AI and business transformation
The company is developing AI-enabled offerings and internal tools while updating technology and processes to improve productivity, including clinical site start-up and the customer buying experience.
IQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk FactorsPursue strategic acquisitions
Management expects to consider acquisitions that strengthen the company's capabilities and expand the services it can offer clients.
IQVIA Holdings Inc. 2025 Form 10-K, Item 1: Growth Strategy
- 2026 adjusted diluted earnings per share, 2026
- $12.80 to $13.00
- IQVIA Reports Second-Quarter 2026 Results
What's changing right now?
Growth is holding steady. In Q3 2026 it sold 8% more than a year earlier. The year before, quarters averaged 8%.
Its operating margin is about where it was a year ago, 13¢ per sales dollar.
Since Oct 2026 the share price has fallen 4%, from $275.07 to $264.73.
Recently
October 27, 2026
GAAP operating margin, quarterly changed to 12.9%
IQVIA Q3 2026 resultsOctober 27, 2026
R&D Solutions quarterly net new bookings changed to $3.2B
IQVIA Q3 2026 results
Coming up
October 27, 2026
Third-quarter 2026 results
IQVIA has scheduled its third-quarter 2026 results announcement and earnings call.
IQVIA Holdings Inc. Investor Relations: Events and PresentationsExpected December 2, 2026
Investor Day
A Q2 2026 earnings-call transcript reports that management was planning an Investor Day; the company may use the event to discuss its business and plans.
IQVIA Holdings Q2 2026 Earnings Call Transcript
Our own estimate moved too: the base case went from $62.31 to $68.42 a share between our last two valuations.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Clinical research contracts may be delayed or canceled
Clients can end many research contracts on short notice, for example after trial setbacks, funding changes, or shifts to competitors. Delays or cancellations can reduce revenue and leave resources underused.
From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors
Access to outside data could be restricted
IQVIA relies on third-party suppliers for data used in some information services. Suppliers could raise prices, limit permitted uses, provide lower-quality data, or stop supplying it, affecting the company's ability to serve clients.
From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors
Privacy rules may limit data use
Privacy and data-protection laws can restrict how IQVIA collects, uses, and transfers health information. New rules or compliance failures could require added spending or limit some services.
From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors
Cyberattacks could disrupt services or expose information
A security breach at IQVIA or a vendor could interrupt operations, expose sensitive data, trigger legal or regulatory costs, and damage trust with clients and data suppliers.
From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors
Competition and technology changes could pressure growth
IQVIA competes with large service and technology firms, clinical research organizations, client in-house teams, and new entrants. If it fails to adapt or clients do less outsourcing, demand and growth could weaken.
From the company's own filingsWould hit how fast sales growIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors
Transformation efforts may not deliver expected savings
The company is changing technology and processes to improve productivity and reduce costs. If these efforts are delayed or do not achieve their goals, its competitiveness and operating results could suffer.
From the company's own filingsWould hit how much of each sale it keepsIQVIA Holdings Inc. 2025 Form 10-K, Item 1A: Risk Factors
Management attributes 0.025 of 2026 revenue growth to acquisitions, which limits what current reported growth says about continuing demand.
From our researchWould hit how fast sales growIQVIA Q3 2026 results
Acquisition spending was 1.714 billion dollars in 2025, substantially above the 589 million dollars spent in the first nine months of 2026, making a stable rate uncertain.
From our researchWould hit how much it has to reinvestIQVIA 2025 results
Is it a good business?
From 2016 to 2025 it earned between 3% and 10% on the capital invested in it, a median of 5%. Its cost of capital in the latest valuation is 8.6%; returns were above it in 4 of the 10 years.
From 2016 to 2025 it earned between 1% and 23% on its shareholders' equity, a median of 16%.
Over 10 years its operating margin ranged from 6¢ to 14¢ per sales dollar, a median of 10¢.
Cost of capital 8.6%
It bought back shares: the count fell 2.7% in a year, so each remaining share owns a slightly bigger slice.
It owes $13.6B more than it holds in cash, about 6.1 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $264.73. Our put its value between $4.91 and $141.68, with $68.42 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $4.91
Despite faster sales this year, clinical work grows more slowly, costs take a larger share of revenue, and expansion uses more cash.
Base case, $68.42
After this year's faster sales, clinical work keeps the business growing while profits recover modestly and expansion continues.
Bull case, $141.68
This year's faster sales turn into lasting gains as more clinical work arrives, while the business keeps more profit from each sale.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 287%
For Iqvia to be worth today's $264.73, sales would need to grow about 27.2% a year. We assume 6.0%. Over the last 5 years, sales grew 5.0% a year.
Or, if sales grow 6.0% as we assume, the price works with a profit margin of 31.2% (we assume 13.5%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 27.2% a year?
Try your own numbersWe're not very sure of this range: it scores 48 out of 100 on our checks. The weakest point is scenario dispersion.
Test the assumptions
Our base value of $68.42 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average6.0%
- Operating margin13.5%
- Long-term growth rate2.2%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$68.42 -74.2%


